Breaking News Instant updates and real-time market news.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

, GLPG

Galapagos NV

$115.19

6.36 (5.84%)

07:12
02/13/18
02/13
07:12
02/13/18
07:12

Vertex halted trials in France as protest, says H.C. Wainwright

H.C. Wainwright analyst Andrew Fein says he learned via Twitter and a news article that Vertex Pharmaceuticals (VRTX) decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis in France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. Releasing patients may inadvertently help Vertex's competitors gain ground, especially Galapagos (GLPG) and Proteostasis (PTI), Fein tells investors in a research note. He keeps a Neutral rating on Vertex shares with a $103 price target.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

GLPG

Galapagos NV

$115.19

6.36 (5.84%)

PTI

Proteostasis

$3.01

0.27 (9.85%)

  • 28

    Feb

VRTX Vertex
$152.01

-0.95 (-0.62%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $190
LEER
Outperform
Vertex price target raised to $190 from $175 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Vertex to $190 from $175 saying "strong" Q4 and triple data offer upside. The analyst reiterates an Outperform rating on the shares.
02/01/18
RBCM
02/01/18
NO CHANGE
Target $200
RBCM
Outperform
Vertex price target raised to $200 from $181 at RBC Capital
RBC Capital RBC Capital analyst Brian Abrahams raised his price target on Vertex to $200 and kept his Outperform rating, saying that Q4 earnings highlighted continued opportunity in the CF market. The analyst adds that the "best-case data from two next-gen correctors show activity even better than game-changing results from first two", setting the stage for pivotal trial starts.
02/01/18
DBAB
02/01/18
NO CHANGE
Target $193
DBAB
Buy
Vertex investors should pay more attention to Galapagos, says Deutsche Bank
Deutsche Bank analyst Navin Jacob raised his price target for Vertex Pharmaceuticals (VRTX) to $193 from $175 following last night's Q4 results and keeps a Buy rating on the shares. The triple efficacy data are better than expected, and create a "very high hurdle" for competitors, Jacob tells investors in a research note. He believes, however, that Vertex investors should be paying more attention to Galapagos NV (GLPG). Galapagos CEO Ono van de Stolpe has "100% confidence" that the company will be getting its first novel triple combo into patients in Q1, Jacob tells investors in a research note after meeting with the executive. The analyst expects some volatility to Vertex shares if Galapagos is able to start the triple trial in Q1. Jacob, however, adds that his math puts Galapagos two-and-a-half years behind Vertex and that the efficacy hurdle is "VERY high."
02/01/18
JEFF
02/01/18
NO CHANGE
Target $195
JEFF
Buy
Jefferies sees Vertex moving higher, ups target to $195
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $195 from $185 and reiterates a Buy rating on the shares following last night's Q4 results. The company's triple pill could triple earnings in the next five years with no biosimilar or generic issues on the horizon, Yee tells investors in a research note. He sees the stock moving higher.
GLPG Galapagos NV
$115.19

6.36 (5.84%)

01/03/18
JEFF
01/03/18
NO CHANGE
Target $185
JEFF
Buy
Vertex competitor's cystic fibrosis update unsurprising, says Jefferies
Jefferies analyst Michael Yee says last night's cystic fibrosis update from Vertex Pharmaceuticals (VRTX) competitor Galapagos NV (GLPG) contained no surprises. None of Galapagos' developments are unexpected, and 2018 remains a period where the Vertex competitor is running a number of "proof of concept" studies to see if it has something, Yee tells investors in a research note. He believes challenges remain for cystic fibrosis competitors because making a triple requires three individual drugs to show minimal drug-drug interactions and have a clean side effect profile. Yee keeps a Buy rating on Vertex with a $185 price target.
09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
PTI Proteostasis
$3.01

0.27 (9.85%)

12/12/17
LEER
12/12/17
NO CHANGE
Target $8
LEER
Proteostasis price target raised to $8 from $6 at Leerink
12/12/17
JMPS
12/12/17
NO CHANGE
Target $200
JMPS
Outperform
Proteostasis data not as positive as Vertex, says JMP Securities
JMP Securities analyst Liisa Bayko says Proteostasis Therapeutics' (PTI) CF programs look positive, but not as positive as Vertex (VRTX) at this point. Nonetheless, the analyst acknowledges that it remains early days for Proteostasis and she still needs to see how its internal triple combination will perform. Bayko reiterates an Outperform rating and $200 price target on Vertex shares.
12/12/17
BARD
12/12/17
NO CHANGE
Target $25
BARD
Outperform
Proteostasis price target nearly doubled to $25 at Baird
Baird analyst Brian Skorney noted that Proteostasis (PTI) reported proof-of-concept data for the company's lead drug, PTI-428, that surpassed his expectations and "clearly confirms" that PTI-428 is biologically active. Though not "as mind-blowing as Vertex's triple data," he would argue that the benefit should be taken at face value and that PTI-428 is a first-in-class "amplifier," Skorney tells investors. The analyst raised his price target on Proteostasis to $25 from $13 on his view of the increased probability of success for PTI-428. Proteostasis Therapeutics shares are up 78% in pre-market trading to $4.19.
08/16/17
LEER
08/16/17
NO CHANGE
Target $9
LEER
Outperform
Proteostasis price target lowered to $9 from $17 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Proteostasis to $9 from $17 but reiterated an Outperform rating on the shares. The analyst notes that competitive developments have raised investor concern about the future of Proteostasis, but believes the company's current market cap of about $60M reflects a worst case scenario that assigns very little if any credit to the company's technology ahead of potentially impactful data in 2H17 and beyond.

TODAY'S FREE FLY STORIES

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TWTR

Twitter

$31.70

0.94 (3.06%)

16:38
02/22/19
02/22
16:38
02/22/19
16:38
Hot Stocks
Twitter board member Evan Williams to step down at end of month »

On February 22, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

ALLY

Ally Financial

$26.95

-0.07 (-0.26%)

16:34
02/22/19
02/22
16:34
02/22/19
16:34
Hot Stocks
Ally Financial CEO sells over 97,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.